A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid‐β oligomers
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Brain accumulation of soluble oligomers of the amyloid‐β peptide (AβOs) is increasingly considered a key early event in the pathogenesis of Alzheimer's disease (AD). A variety of AβO species have been identified, both in vitro and in vivo, ranging from dimers to 24mers and higher order oligomers. However, there is no consensus in the literature regarding which AβO species are most germane to AD pathogenesis. Antibodies capable of specifically recognizing defined subpopulations of AβOs would be a valuable asset in the identification, isolation, and characterization of AD‐relevant AβO species. Here, we report the characterization of a human single chain antibody fragment (scFv) denoted NUsc1, one of a number of scFvs we have identified that stringently distinguish AβOs from both monomeric and fibrillar Aβ. NUsc1 readily detected AβOs previously bound to dendrites in cultured hippocampal neurons. In addition, NUsc1 blocked AβO binding and reduced AβO‐induced neuronal oxidative stress and tau hyperphosphorylation in cultured neurons. NUsc1 further distinguished brain extracts from AD‐transgenic mice from wild type (WT) mice, and detected endogenous AβOs in fixed AD brain tissue and AD brain extracts. Biochemical analyses indicated that NUsc1 targets a subpopulation of AβOs with apparent molecular mass greater than 50 kDa. Results indicate that NUsc1 targets a particular AβO species relevant to AD pathogenesis, and suggest that NUsc1 may constitute an effective tool for AD diagnostics and therapeutics. image
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“Others have proposed a primary pathogenic role for higher molecular weight soluble AbOs, that is, greater than 50 kDa (Gong et al. 2003; Lesne et al. 2006; Velasco et al. 2012; Mc Donald et al. 2015; Savioz et al. 2016).”
RetractedOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 4×
“Phage-bound NUsc1 also readily discriminated brain extracts from 5xFAD (Oakley et al. 2006) or WT mice in an ELISA assay, similar to the polyclonal anti-AbO IgG m70 (Lambert et al. 2001) (Fig.”
InfluentialThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“(2017) 142, 934--947 related imaging abnormalities (vasogenic edema and microhemorrhages) (Farlow and Brosch 2013; Goure et al. 2014; Sevigny et al. 2016).”
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · cited 1×
“Although the toxicity of AbOs was identified almost 20 years ago (Lambert et al. 1998), the identity of the most Alzheimer’s Disease-relevant AbO species remains unknown (Benilova et al. 2012; Viola and Klein 2015).”
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 1×
“Phage-bound NUsc1 reacted with Ab oligomers in fixed brain sections from APP/PS1 mice (Jankowsky et al. 2004) (Fig.”
An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · cited 4×
“In culture, NUsc1 detected synthetic AbOs previously bound to neurons in a punctate pattern along dendrites, similar to previous observations using anti-AbO IgGs and suggesting that the AbOs targeted by NUsc1 bind synapses (Lacor et al. 2007).”
InfluentialSelf-citationGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 8×
“Because of the non-abundance of AbOs in AD brain as well as their instability andmolecular heterogeneity (Teplow2013), antibodies have played a prominent role in the identification and characterization of AD-relevant AbOs.”
InfluentialSelf-citationSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954 · cited 1×
“In this case, autopsied brain sections from AD patients and cognitively normal subjects (Northwestern University CNADC) were immunolabeled as described in Lacor et al. (2004).”
Self-citationDe Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · cited 4×
“ROS levels were determined using the ROS-sensitive probe DCFDA, as described (De Felice et al. 2007).”
InfluentialSelf-citationThe Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · cited 2×
“Neuroprotection by NUsc1 was tested by analyzing its capacity to block or reduce AbO-induced toxic events in rat hippocampal neurons, namely excessive ROS accumulation (De Felice et al. 2007, 2009) and tau hyperphosphorylation (De Felice et al. 2008).”
Self-citationAmyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628 · cited 2×
“A number of antiAb conformational-specific antibodies have been developed (Goure et al. 2014; Murakami 2014; Viola and Klein 2015) and utilized to characterize distinct AbO conformations, including annular protofibrillar oligomers (Kayed et al. 2009), amylospheroids (Noguchi et al. 2009; Matsumura…”
Self-citationStability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
Self-Assembly of Aβ 1 - 42 into Globular Neurotoxins
Chromy, B. A., Nowak, R. J., Lambert, M. P., Viola, K. L., Chang, L., Velasco, P. T., Jones, B. W., Fernandez, S. J., Lacor, P. N., Horowitz, P., et al. (2003) · Biochemistry · doi:10.1021/bi030029q · Cited by 522 · cited 2×
“Briefly, AbOs were prepared using Ab1-42 (American Peptide, Sunnyvale, CA,USA) as in (Chromy et al. 2003).”
Self-citationAlzheimer Disease and Oxidative Stress
Perry, G., Cash, A. D., & Smith, M. A. (2002) · BioMed Research International · doi:10.1155/s1110724302203010 · Cited by 455 · cited 2×
“…although ROS production is physiological under certain levels/circumstances (e.g., Sena and Chandel 2012), excessive ROS production is toxic to most cells, and is a toxic event implicated in the pathogenesis of AD (Perry et al. 2002) and known to be induced by AbOs (De Felice et al. 2007, 2009).”
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442 · cited 2×
“…934--947 Evidence obtained during the past two decades implicates the accumulation of soluble Ab oligomers (AbOs) in the brain, rather than fibrillar Ab deposits in plaques, as the primary synaptotoxic form of Ab (Ferreira and Klein 2011; Hayden and Teplow 2013; Klein 2013; Selkoe and Hardy 2016).”
Self-citationAlzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432
Self-citationVaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies
Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00592.x · Cited by 349 · cited 3×
“Phage-bound NUsc1 also readily discriminated brain extracts from 5xFAD (Oakley et al. 2006) or WT mice in an ELISA assay, similar to the polyclonal anti-AbO IgG m70 (Lambert et al. 2001) (Fig.”
Self-citationMonoclonal antibodies that target pathological assemblies of Aβ
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314 · cited 11×
“The punctate dendritic labeling pattern obtained with NUsc1 closely resembles the pattern obtained using our AbO-selective polyclonal or monoclonal antibodies (Lambert et al. 2001, 2007) and indicates targeting of AbOs bound to synapses.”
InfluentialSelf-citationAmyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276 · cited 1×
“…934--947 Evidence obtained during the past two decades implicates the accumulation of soluble Ab oligomers (AbOs) in the brain, rather than fibrillar Ab deposits in plaques, as the primary synaptotoxic form of Ab (Ferreira and Klein 2011; Hayden and Teplow 2013; Klein 2013; Selkoe and Hardy 2016).”
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190 · cited 2×
“A number of antiAb conformational-specific antibodies have been developed (Goure et al. 2014; Murakami 2014; Viola and Klein 2015) and utilized to characterize distinct AbO conformations, including annular protofibrillar oligomers (Kayed et al. 2009), amylospheroids (Noguchi et al. 2009; Matsumura…”
Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies
Hillen, H., Barghorn, S., Striebinger, A., Labkovsky, B., Müller, R., Nimmrich, V., Nolte, M. W., Perez-Cruz, C., van der Auwera, I., van Leuven, F., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5721-09.2010 · Cited by 113
Amyloid-β Triggers the Release of Neuronal Hexokinase 1 from Mitochondria
Saraiva, L. M., Seixas da Silva, G. S., Galina, A., da-Silva, W. S., Klein, W. L., Ferreira, S. T., & De Felice, F. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015230 · Cited by 94 · cited 1×
“(2017) 142, 934--947 Saraiva et al. 2010; Figueiredo et al. 2013) using the fluorescent probe CM-H2DCFDA (Invitrogen).”
Self-citation
Cited by
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Self-citationLi, S., & Selkoe, D. J. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15007 · Cited by 263
A genetically encoded selection for amyloid-β oligomer binders
Lee, B., Mannone, J. A., & Wang, T. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01975-4 · Cited by 3
Metadata
- Authors
- Sebollela, A., Cline, E. N., Popova, I., Luo, K., Sun, X., Ahn, J., Barcelos, M. A., Bezerra, V. N., Lyra e Silva, N. M., Patel, J., Pinheiro, N. R., Qin, L. A., Kamel, J. M., Weng, A., DiNunno, N., Bebenek, A. M., Velasco, P. T., Viola, K. L., Lacor, P. N., Ferreira, S. T., & Klein, W. L.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2017-08-02
- Volume
- 142
- Issue
- 6
- Pages
- 934-947
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2728967629
- Cited by
- 35
- References
- 24
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.